Table 1.

Characteristics of 163 postmenopausal women with rheumatoid arthritis participating in study

	N(%) or Mean (± SD) or Median (IQR)
Age	62.4 (± 9.0)
Body mass index	28.6 (± 6.6)
Duration with rheumatoid arthritis	13.7 (±10.9)
Rheumatoid factor status positive	97 (63%)
C-Reactive Protein (mg/dl)*	2.8 (1.3–6.6)
Disease Activity Score (DAS28 – CRP)	3.8 (± 1.6)
History of oral glucocorticoid use	112 (69%)
Cumulative oral glucocorticoid dosage (milligrams)*	2,520 (960–12,720)†
Use of DMARD during follow-up, non-TNF antagonist	116 (71%)
Use of TNF antagonist during follow-up	72 (44%)
Modified Health Assessment Questionnaire*	0.70 (0.3–1.9)
Exercise (days per week)	1.0 (1 – 4)
History of fractures	19 (12%)
Maternal history of fractures	33 (20%)
Total calcium intake (mg) ‡	929 (± 332)
Use of calcium supplements	71 (44%)
Serum 25-OH vitamin D level (ng/dl)	29 (± 11)
Vitamin D deficient (<20 ng/dl)	29 (20%)
Use of vitamin D supplements	125 (77%)
Use of a bisphosphonate in the past	30 (18%)
Use of a non-bisphosphonate OP medication in the past	75 (46%)

OP, osteoporosis.

^*Median and interquartile range

^†Among the 112 with some prior use of oral glucocorticoids.

^‡Dietary sources plus supplements.

During the study period, no patients were receiving abatacept or rituximab.